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Secondary pituitary enlargement due to primary hypothyroidism is not a common mani-
festation. The loss of thyroxin feedback inhibition in primary hypothyroidism causes over-
production of thyrotropin-releasing-hormone (TRH), which results in secondary pituitary 
enlargement. TRH has a weak stimulatory effect on the lactotroph cells of the pituitary, 
so a mild to moderate increase in prolactin (PRL) levels is expected. We report the case 
of a 67-year-old female who presented with a large pituitary mass and a very high level 
of TSH in association with a significant rise in PRL level. In this case, diagnosing a sellar 
mass was challenging; it was difficult to distinguish between pituitary prolactinoma and 
primary hypothyroidism with secondary pituitary hyperplasia. Thyroid hormone replace-
ment proved that this patient’s hyperprolactinemia was due to hyperplasia of the pituitary 
gland. As such, making the correct diagnosis and initiating thyroid hormone therapy can 
prevent unnecessary treatment with dopamine agonists.
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INtRoDUCtIoN
Secondary pituitary enlargement due to primary hypothyroidism is not a common occurrence. 
Even with recent imaging techniques, secondary pituitary gland enlargement is sometimes difficult 
to differentiate from the presence of a functional pituitary adenoma (1–3). Pituitary enlargement is 
the result of an overproduction of thyrotropin-releasing hormone (TRH) due to a loss of thyroxin 
feedback inhibition in primary hypothyroidism (4). TRH increases thyroid-stimulating hormone 
(TSH) from the pituitary gland in an attempt to elevate thyroxin levels to normal physiological 
levels; this long-standing hypothyroidism causes hyperplasia of the pituitary’s thyrotrophic cells 
(5). There are many causes of sellar and supra-sellar pituitary enlargement; primary hypothyroidism 
is one of them, and it may even present with symptoms of elevated prolactin (PRL) levels with a 
pituitary mass. However, high PRL levels in such cases are not the result of a prolactinoma itself; 
rather, they are due to the effect of TRH on lactotroph cells (6, 7). TRH has a weak stimulatory effect 
on lactotroph cells, so a mild to moderate increase in PRL levels is expected (5). We report the case 
of a 67-year-old female who presented with a large pituitary mass and a very high level of TSH with 
a marked rise in PRL level.
Case RepoRt
A 67-year-old postmenopausal female, who is a known diabetic on oral hypoglycemic agents, 
presented with a history of two episodes of loss of consciousness and jerky limb movements. She 
had a history of intermittent headaches, which responded to simple analgesics, and these headaches 
taBLe 1 | Hormone profile at baseline (December 2013) and in subsequent follow-up visits with treatment.
serum hormone level December 2013 February 2014 June 2014 January 2015
TSH [mIU/L (Ref: 0.2–4.2)] 863.3 38.98 97.97 1.35
Free T4 [pmol/L (Ref: 12–20)] 1.9 10.8 9.6 16.2
PRL [mIU/L (Ref: 102–496)] 3,234 870 400 442
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did not interfere with her daily activities. She did not have any 
risks for seizures, nor did she have a history of a cerebrovascular 
accident. As part of a workup for seizure disorder, she was found 
to have a large sellar mass upon brain magnetic resonance imag-
ing (MRI). A history of galactorrhea, thyroid disease, symptoms 
of growth hormone excess, Cushing’s syndrome, and visual field 
defects was absent.
On clinical examination, her blood pressure was 130/70 mmHg 
with a pulse rate of 84 beats/min. Her complete systemic exami-
nation was normal, apart from a delay in the relaxation phase of 
her deep tendon reflexes. The thyroid gland was not enlarged.
Her blood workup showed a very high level of TSH, as 
well as low thyroxin (T4) and high PRL levels (see Table  1). 
Other pituitary hormone levels [adrenocorticotropic hormone 
(ACTH), 8.4 pmol/L; growth hormone (GH), 0.5 mIU/L; follicle-
stimulating hormone (FSH), 49.1  IU/L; luteinizing hormone 
(LH), 8.6 IU/L; and cortisol, 358 nmol/L] were normal. Thyroid 
peroxidase antibodies (TPO) were also positive.
A dedicated pituitary MRI scan demonstrated a large 
sellar and supra-sellar mass measuring approximately 
1.9 cm × 1.6 cm × 1.8 cm that reached, and probably involved, the 
right cavernous sinus, resulting in a mass effect on the optic chiasm 
and pre-chiasmatic optic nerves, particularly on the right side.
Based on the patient’s clinical and biochemical features and 
MRI findings, a presumptive diagnosis of primary hypothyroid-
ism with pituitary hyperplasia was entertained; she was started on 
50 mcg of thyroxin daily, with further escalation of the thyroxine 
dose as per her blood thyroid function testing. She continued her 
diabetes medication along with this treatment. The patient’s serial 
thyroid function and pituitary hormone profile were assessed to 
adjust the thyroxin dose accordingly. The patient’s TSH and PRL 
levels came down gradually and became normal in subsequent 
follow up. Her clinical symptoms improved, as she experienced 
fewer headaches and she did not exhibit any further abnormal 
movements at her various follow-up visits.
DIsCUssIoN
Pituitary enlargement secondary to primary hypothyroidism pre-
sents as hyperplasia of the pituitary’s endocrine cells and changes 
in the pituitary’s structure (8). Pituitary hyperplasia can include 
a slight increase in pituitary cell mass without much change 
in pituitary architecture, or the great enlargement of the gland 
with variations in both tissue architecture and morphology (9). 
Hashimoto’s thyroiditis has a chronic course with an insidious 
onset of clinical signs and symptoms, for which diagnosis and 
treatment are typically delayed. Low levels of serum FT3 and FT4 
cause a loss of thyroxin feedback inhibition and the subsequent 
overproduction of thyrotropin-releasing hormone (TRH); it is 
followed by hyperplasia and hypertrophy of thyrotrophic cells, 
as well as enlargement of the pituitary gland (4), which was also 
expected in our patient. Given that TRH not only stimulates 
pituitary thyrotrophic cells but it also has a weak stimulatory 
effect on lactotroph cells, variable hyperprolactinemia may be 
seen in a good number of cases of primary hypothyroidism 
(5). Yamada et  al. demonstrated positive correlation between 
increased sizes of the sella turcica and serum levels of TSH (10). 
Apart from the stimulatory effect of TRH on lactotrophs, in pri-
mary hypothyroidism, pituitary cells also have reduced sensitivity 
to dopamine’s inhibitory effect on receptor and post-receptor 
levels (11). On the other hand, 3,5,3′ tri-iodothyronine (T3) was 
shown to decrease PRL mRNA levels in pituitary cells. Therefore, 
reduced thyroid hormone levels will lead to more PRL synthesis 
(12). In fact, in hypothyroidism, PRL clearance from circulation 
is also reduced (13). The pituitary enlargement itself can cause a 
stalk effect, blocking dopamine’s inhibitory effect on lactotrophs, 
thus contributing to hyperprolactinemia.
Clinically, these cases can present with visual field defects and 
headaches, as well as other signs and symptoms related to high 
PRL levels, including galactorrhea or menstrual irregularities 
in women, and erectile dysfunction and loss of libido in men. 
As our patient was postmenopausal, these symptoms were not 
reported at all.
The differential diagnosis for a pituitary mass should include 
secondary enlargement from any endocrine end organ dysfunc-
tion, a TSH-secreting adenoma, and prolactinomas (14). Despite 
recent progress in pituitary imaging, hyperplasia may be misinter-
preted as a pituitary adenoma, even using MRI with gadolinium 
injection, particularly in the presence of hyperprolactinemia 
(15). Secondary pituitary hyperplasia is often characterized by 
a homogeneously enhanced lesion on MRI that may progress 
rapidly following the onset of hypothyroidism (16), which was 
evident in our case per the post-contrast MRI images (Figure 1). 
A trial of thyroxin replacement for 6–12 weeks with repeat MRI 
after 12  weeks may help to correctly diagnose pituitary hyper-
plasia (17). Appropriate diagnosis and treatment are of utmost 
importance, as they can help avoid unnecessary treatment with 
dopamine agonists. MRI is superior to computed tomography 
(CT) scan when imaging the pituitary, and follow-up imaging 
further helps to monitor changes in pituitary size (18).
Thyroxin hormone replacement is the most important treat-
ment for hypothyroidism and the duration of treatment should 
not be <4 months (18). In our case, serum TSH and PRL levels 
started declining with thyroxin replacement; this replacement 
may need to be lifelong. Thyroxin therapy is started with a low 
dose and it is gradually increased every 4–6  weeks. Thyroid 
function tests must be performed regularly during the course 
of therapy, and doses are adjusted according to the results (18). 
FIGURe 1 | Diffuse pituitary enlargement of 1.9 cm × 1.6 cm × 1.8 cm in size is noted in pre-treatment MRI images; post-contrast images show 
diffuse enhancement, as well as a mass reaching up to right cavernous sinus and elevating to the optic chiasm. In the last image, a thickened pituitary 
stalk is seen, which deviates from the midline.
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Surgery is reserved for decompression of the optic chiasm and 
optic nerve, or to obtain a tissue diagnosis in case the mass does 
not respond to or becomes worse with thyroid hormone replace-
ment. Our case showed a good response to thyroxin replacement; 
the post-contrast images (Figure 2) also showed a regression in 
mass size, and the optic chiasm was free from the pituitary mass. 
In subsequent follow up, another MRI was done in April 2015 
(Figure 3), but it did not show any interval changes. If, in the 
course of follow up with thyroid hormone replacement, the TSH 
levels partially decline and no improvement in the pituitary mass 
is seen, a diagnosis of TSH-secreting adenoma of the anterior 
pituitary must be considered and surgical resection through a 
trans-sphenoidal approach is advised (19). On the other hand, if 
the TSH level is suppressed with no changes in the serum PRL 
levels after more than 6 months of thyroxin replacement, and if 
there is no MRI evidence of mass shrinkage and no improvements 
in the symptoms of galactorrhea or amenorrhea, a PRL-secreting 
adenoma should be suspected (20).
There have been a number of reports in the literature featuring 
other successful instances where thyroxin replacement therapy 
was used to treat hyperprolactinemia. For instance, a case of 
severe symptomatic hypothyroidism featuring hyperprolactine-
mia, a pituitary mass, and the development of an empty sella after 
thyroxin replacement has been reported (21). Similarly, a case 
series of five patients with hypothyroidism – who also presented 
with pituitary masses and high PRL levels – responded to thyroxin 
replacement, leading to the resolution of the pituitary mass in all 
cases; even one patient developed an empty sella post-treatment 
(22). More recently, Neves et al. also reported a case of primary 
hypothyroidism presenting with mild hyperprolactinemia and a 
pituitary mass with features of mass effect and amenorrhea; this 
patient also improved with thyroxin replacement alone (23).
Interestingly, our patient had very high PRL (3,234 mIU/L) 
and TSH levels at diagnosis; her presentation was very different 
from those of the previously reported cases, as she had seizures 
and a history of unconsciousness alone. She did not exhibit 
any clinical features of hypothyroidism or hyperprolactinemia, 
although she did have a large pituitary mass. We decided to put 
her on thyroxin therapy, as she was not having any symptoms 
of hyperprolactinemia. In subsequent follow-up investigations, 
her PRL level reduced in association with her TSH level, and 
after 6  months, both levels were completely normal. As such, 
we concluded that our patient had hyperprolactinemia due to 
a lactotrophic effect of TRH in addition to pituitary thyrotroph 
hyperplasia secondary to primary hypothyroidism.
CoNCLUsIoN
Primary hypothyroidism should be considered as a differential 
diagnosis of diffuse pituitary enlargement with high TSH levels. 
MRI is superior to CT scan in making this diagnosis, and follow-
up images assist in further monitoring the changes in pituitary 
size with treatment. Interpretation of a pituitary mass without 
proper endocrine evaluation and investigations can lead to 
FIGURe 3 | Follow-up MRI of a pituitary mass measuring 11 mm in 
height, which is near normal; the optic chiasm is seen to be free and 
the stalk is in the midline.
FIGURe 2 | Repeated MRI once again showed a pituitary mass, measuring about 11 mm in height, which was reduced in size in comparison to the 
previous height of 18 mm. There was no compression of the optic chiasm or optic nerves. The pituitary stalk is in the center and no shift was noted.
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mismanagement and unnecessary dopamine agonist treatment; 
hence, knowledge of this entity is of paramount importance.
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